Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Lymphoma 2Neuroendocrine Tumors 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoid Tumor 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × CX 3543 × Clear all
NCT00780663 2011-06-15

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Cylene Pharmaceuticals

Phase 2 Completed
25 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT00955292 2009-08-10

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma

NCT00955786 2009-08-10

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

Phase 1 Completed
48 enrolled
Lymphoid

Lymphoma

NCT00485966 2008-11-05

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Cylene Pharmaceuticals

Phase 2 Withdrawn
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡